Causes and Associations of Raynaud's Phenomenon

Primary and Secondary Forms

Raynaud's phenomenon can occur as a primary (idiopathic) condition or secondary to various underlying disorders, with systemic sclerosis being the most common associated condition 1, 2
Primary Raynaud's phenomenon occurs as an isolated condition without an underlying disease 1

Autoimmune and Connective Tissue Diseases

Systemic sclerosis (scleroderma) is the most common association with secondary Raynaud's phenomenon 3, 4
Systemic lupus erythematosus is associated with secondary Raynaud's phenomenon 1, 2
Rheumatoid arthritis is associated with secondary Raynaud's phenomenon 1

Vascular Disorders

Thromboangiitis obliterans (Buerger's disease) is particularly associated with secondary Raynaud's phenomenon in young tobacco smokers 1, 2
Atherosclerosis with peripheral arterial disease is associated with secondary Raynaud's phenomenon 1
Thromboembolic disease (both macroembolic and microembolic) is associated with secondary Raynaud's phenomenon 1

Hematologic and Prothrombotic Conditions

Abnormalities in the clotting system (protein C, protein S, or antithrombin III deficiencies) are associated with secondary Raynaud's phenomenon 1
Factor V Leiden or prothrombin mutations are associated with secondary Raynaud's phenomenon 1
Hyperhomocysteinemia is associated with secondary Raynaud's phenomenon 1
Presence of lupus anticoagulant or anticardiolipin antibody is associated with secondary Raynaud's phenomenon 1
Prothrombotic states associated with malignancies are associated with secondary Raynaud's phenomenon 1
Inflammatory bowel disease-related prothrombotic states are associated with secondary Raynaud's phenomenon 1

Occupational and Environmental Factors

Cold exposure (chronic) is associated with secondary Raynaud's phenomenon 5
Radiation-associated arteritis is associated with secondary Raynaud's phenomenon 1

Drug-Induced Causes

Ergot alkaloids can induce Raynaud's phenomenon 6
Bleomycin can induce Raynaud's phenomenon 6
Clonidine can induce Raynaud's phenomenon 6
Beta-blockers may be clinically relevant in inducing Raynaud's phenomenon 4

Other Conditions

Primary biliary cirrhosis is associated with secondary Raynaud's phenomenon 7
Malignancies (paraneoplastic phenomenon) are associated with secondary Raynaud's phenomenon 3

Treatment Implications

The American College of Rheumatology recommends that the treatment approach differs based on whether Raynaud's is primary or secondary, with secondary Raynaud's potentially requiring more aggressive pharmacological therapy including calcium channel blockers, phosphodiesterase-5 inhibitors, prostacyclin analogs, or endothelin receptor antagonists 4, 6

Diagnostic Criteria and Treatment Options for Raynaud's Phenomenon

Diagnostic Criteria

Severe, painful episodes with digital ulceration can be a red flag for secondary Raynaud's 8

Treatment Options

Avoidance of known triggers, such as cold exposure, trauma, stress, smoking, and vibration injury, is recommended for patients with Raynaud's phenomenon 8
Proper warm clothing in cold conditions, including a coat, mittens, hat, and insulated footwear, can help manage symptoms 8
Physical therapy to stimulate blood flow and exercises to generate heat can be beneficial for patients with Raynaud's phenomenon 8
Calcium channel blockers, particularly nifedipine, are the most prescribed and studied medications for Raynaud's phenomenon 8
Phosphodiesterase-5 inhibitors, such as sildenafil, can be used as second-line therapy for patients with inadequate response to calcium channel blockers 8
Prostacyclin analogues can be used as third-line therapy for patients who fail to respond to second-line therapy 8
Endothelin-1 receptor antagonists, such as bosentan, can be used to prevent new digital ulcers in systemic sclerosis 8
PDE5 inhibitors are effective for both healing and prevention of digital ulcers 8
In severe cases with gangrene or osteomyelitis, amputation might be required 8
Limited evidence supports the use of biofeedback, acupuncture, and ceramic-impregnated gloves 8
Other treatments with minimal evidence include antioxidants, essential fatty acids, Ginkgo biloba, and L-arginine 8
Digital ulcers and gangrene are serious complications that occur more frequently in secondary Raynaud's, particularly in systemic sclerosis 8

Treatment Options for Raynaud's Phenomenon

First-Line Treatment

The European League Against Rheumatism recommends dihydropyridine-type calcium channel blockers, particularly nifedipine, as first-line therapy for Raynaud's phenomenon, due to their clinical benefit, low cost, and acceptable adverse effects 9, 10
Other dihydropyridine-type calcium channel blockers can be considered if there is a lack of benefit from or poor tolerability of nifedipine 10
Meta-analyses of randomized controlled trials confirm that nifedipine reduces both frequency and severity of Raynaud's attacks 9, 11

Second-Line Treatment

Phosphodiesterase-5 inhibitors, such as sildenafil and tadalafil, should be considered when calcium channel blockers provide an inadequate response, as they effectively reduce frequency and severity of Raynaud's attacks 9, 11
The American College of Rheumatology suggests that phosphodiesterase-5 inhibitors are also effective for both healing and prevention of digital ulcers, though results for prevention are mixed 12
Cost and off-label use may limit phosphodiesterase-5 inhibitor utilization 12

Third-Line Treatment

Intravenous prostacyclin analogues, such as iloprost, should be considered for severe Raynaud's phenomenon that is unresponsive to oral therapies, as they have demonstrated efficacy in reducing frequency and severity of attacks 9, 11

Digital Ulcer Management

For prevention of new digital ulcers, especially in systemic sclerosis, bosentan, an endothelin receptor antagonist, is effective, particularly in patients with multiple digital ulcers 12
Phosphodiesterase-5 inhibitors and prostacyclin analogues can be used for both healing and prevention of digital ulcers 12
Intravenous iloprost has proven efficacy for healing of existing digital ulcers 9, 11
Phosphodiesterase-5 inhibitors improve healing of digital ulcers 11, 12

Other Pharmacological Options

Fluoxetine, a selective serotonin reuptake inhibitor, might be considered for Raynaud's attacks, though evidence is limited to small studies 9, 11
Atorvastatin showed potential for preventing new digital ulcers in a small trial, but is not included in major guidelines 12

Non-Pharmacological Measures

Avoidance of known triggers, such as cold exposure, trauma, stress, smoking, vibration injury, and certain drugs, is essential for managing Raynaud's phenomenon 12
Proper warm clothing in cold conditions, such as a coat, mittens, hat, insulated footwear, and hand/foot warmers, is recommended 12
Physical therapy to stimulate blood flow and exercises to generate heat can be beneficial for patients with Raynaud's phenomenon 12

Treatment Algorithm Based on Severity

For mild Raynaud's phenomenon, non-pharmacological measures and calcium channel blockers, such as nifedipine, can be considered if symptoms affect quality of life 9, 10
For moderate to severe Raynaud's or inadequate response to calcium channel blockers, phosphodiesterase-5 inhibitors can be added or used as an alternative 9
For severe Raynaud's with frequent attacks despite above treatments, intravenous prostacyclin analogues can be considered 9
For digital ulcers, bosentan, phosphodiesterase-5 inhibitors, or prostacyclin analogues can be used for prevention, and intravenous iloprost or phosphodiesterase-5 inhibitors can be used for healing 9, 12

Treatment of Painful Raynaud's Phenomenon

Non-Pharmacological and Pharmacological Interventions

Cold protection strategies, such as wearing mittens and insulated footwear, can help reduce the frequency of painful attacks, as recommended by the guidelines from Nature Reviews Rheumatology 13
Phosphodiesterase-5 inhibitors, such as sildenafil or tadalafil, can be added or switched to when calcium channel blockers provide inadequate pain relief, and are particularly valuable if digital ulcers are present, according to Nature Reviews Rheumatology 13
Intravenous iloprost can be considered for severe, painful Raynaud's unresponsive to oral therapies, and is particularly effective for healing digital ulcers, as stated in Nature Reviews Rheumatology 13
Bosentan, an endothelin receptor antagonist, is most effective for preventing new digital ulcers, especially if ≥4 digital ulcers are present at baseline, as recommended by Nature Reviews Rheumatology 13
Topical nitroglycerin can provide ancillary benefit for acute painful episodes, according to Nature Reviews Rheumatology 13
Atorvastatin showed promise for preventing new digital ulcers in small trials, as reported in Nature Reviews Rheumatology 13
Digital sympathectomy can be considered for refractory cases with persistent digital ulcer healing/prevention needs, as stated in Nature Reviews Rheumatology 13
Botulinum toxin infiltrations or fat grafting have emerging evidence supporting their use for healing and prevention of digital ulcers, according to Nature Reviews Rheumatology 13

Diagnosing and Managing Raynaud's Phenomenon

Diagnostic Approach and Management

The American Heart Association recommends ordering a complete blood count with differential, erythrocyte sedimentation rate, antinuclear antibodies (ANA), rheumatoid factor, anticentromere and anti-Scl-70 antibodies, anticardiolipin antibodies, and lupus anticoagulant when secondary Raynaud's is suspected, as outlined in the Circulation journal 14
The American College of Cardiology suggests that ankle-brachial index can be used to exclude structural macro- or microvascular disease in patients with suspected peripheral arterial disease 14
Thromboangiitis obliterans (Buerger's disease) is a vascular disorder that can cause secondary Raynaud's, particularly in young tobacco smokers, according to the Circulation journal 14

Pharmacological Treatment

The European League Against Rheumatism recommends nifedipine as the first-line pharmacological treatment for Raynaud's phenomenon requiring medication, as it reduces both frequency and severity of attacks, benefiting approximately two-thirds of patients 15
The American College of Rheumatology suggests that phosphodiesterase-5 inhibitors, such as sildenafil or tadalafil, can be added or switched to if calcium channel blockers provide inadequate response, as they are effective in reducing frequency, duration, and severity of attacks 15
The National Institute for Health and Care Excellence recommends intravenous iloprost for severe Raynaud's unresponsive to oral therapies, as it is the only prostacyclin analogue proven effective for Raynaud's in systemic sclerosis 15

Management of Digital Ulcers

The American College of Rheumatology recommends bosentan for prevention of new digital ulcers in patients with systemic sclerosis and recurrent digital ulcers, as it prevents new digital ulcers but does not improve healing 15
The European League Against Rheumatism suggests that intravenous iloprost or phosphodiesterase-5 inhibitors can be used for healing digital ulcers, as they reduce the number of digital ulcers and promote healing 15
The National Institute for Health and Care Excellence recommends wound care by specialized nurses/physicians, antibiotics only when infection is suspected, and pain control as essential for managing digital ulcers 15

Management of Raynaud’s Phenomenon in Systemic Sclerosis

Epidemiology

Raynaud’s phenomenon occurs in nearly all individuals with systemic sclerosis and is frequently the first clinical sign of the disease. 16

First‑Line Pharmacologic Therapy (All Forms of Raynaud’s)

Dihydropyridine calcium‑channel blockers, especially nifedipine, are recommended as the initial treatment to reduce vasospastic episodes. [16][17]

Second‑Line Therapies for Systemic‑Sclerosis‑Associated Raynaud’s (Inadequate Response to CCBs)

Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) are advised when calcium‑channel blockers do not achieve sufficient symptom control. [16][17]
Intravenous iloprost is indicated for severe, refractory Raynaud’s attacks in systemic sclerosis patients. [16][17]

Strategies to Prevent Digital Ulcers in Systemic Sclerosis

Bosentan, an endothelin‑receptor antagonist, is shown to lower the incidence of new digital ulcers in systemic sclerosis‑related Raynaud’s. [16][17]

Rheumatology‑Centered Management of Raynaud’s Disease

Primary Specialist Role

Rheumatologists should be the primary specialists managing Raynaud’s disease, especially when secondary causes or connective‑tissue disease are suspected. 18

Importance of Early Referral

Early referral to rheumatology for patients with suspected secondary Raynaud’s phenomenon is critical because delays are a major cause of postponed effective treatment for connective‑tissue‑disease‑associated Raynaud’s. 19

Outcome Advantages of Rheumatology Care

Compared with other physicians, rheumatologists achieve superior outcomes: they diagnose earlier, prescribe disease‑modifying therapies more frequently, and patients experience better prevention of joint damage and preservation of physical function. 20

Specialized Therapeutic Expertise

Rheumatologists possess specialized expertise in disease‑activity monitoring using validated instruments and have comprehensive knowledge of indications, contraindications, and adverse‑effect profiles of advanced therapies such as phosphodiesterase‑5 inhibitors, endothelin‑receptor antagonists, and prostacyclin analogues. 21
This expertise has become increasingly important with the introduction of modern biologic agents and complex treatment strategies for connective‑tissue‑disease‑related Raynaud’s. 22

Multidisciplinary Collaboration

Primary‑care physicians play a collaborative role in the shared management of uncomplicated primary Raynaud’s and in ongoing monitoring, particularly in settings with limited rheumatology resources. 19

Preventing Referral Delays

Avoiding delays in rheumatology referral when red‑flag features (e.g., severe pain, digital ulceration, systemic symptoms) are present is the most significant preventable cause of poor outcomes. 20